BIO-TECHNE AND NOVOMOL-Dx ANNOUNCE POINT-OF-CARE OCULAR BIOMARKER ASSAY
- The Bio-Marker Pathfinder (BMP) is a revolutionary ocular biomarker kit developed by Bio-Techne (NASDAQ: TECH) and Novomol-Dx for point-of-care applications.
- The BMP kit operates on Bio-Techne's Ella™ platform, offering accurate, reliable data within 90 minutes, focusing on Dry Eye Disease, Diabetic Retinopathy, and post-surgery patient monitoring.
- The partnership aims to address the unmet need for improved ocular diagnostic tools in India, potentially benefiting millions of patients with ophthalmic diseases.
- The collaboration between Bio-Techne and Novomol-Dx highlights the transformative potential of biomarker research in ocular healthcare, paving the way for innovative diagnostic and prognostic solutions.
- The BMP kit leverages cutting-edge technology to provide clinicians with actionable data using tear samples, revolutionizing the diagnosis and treatment of various ocular conditions.
- None.
The collaboration between Bio-Techne and Novomol-Dx on the development of the Bio-Marker Pathfinder (BMP) kit signifies a strategic move into the point-of-care diagnostic space within ophthalmology. Bio-Techne's platform, Ella, serves as the technological backbone for this innovation, with its capability for multiplexing and automated immunoassays positioning it as a highly scalable tool.
From an investment standpoint, this partnership could enhance Bio-Techne's market penetration in diagnostics, a sector that commands high price-earnings ratios due to its stable demand and growth potential. The application of artificial intelligence to create predictive algorithms is indicative of the forward-thinking approach these companies are taking and it may lead to first-mover advantages in ocular diagnostics. Investors should monitor the adoption rates of BMP post-launch, as high clinical effectiveness will likely translate to increased sales and revenue growth.
Considering India's large patient base, the potential market size could significantly impact Bio-Techne's valuation. However, regulatory hurdles and market acceptance are critical factors to watch. Moreover, the scalability of this technology to other diseases could represent future revenue streams, further diversifying Bio-Techne's product portfolio.
The introduction of the BMP kit for ocular conditions such as Dry Eye Disease and Diabetic Retinopathy represents a leap forward in the field of ophthalmic diagnostics. The use of tear samples for clinically actionable data is an innovation that promises to simplify and streamline the diagnostic process for clinicians and patients. The accuracy and reproducibility of Ella's microfluidic-based cartridges are essential features, especially in India's vast patient population.
From a research perspective, the proprietary algorithm and AI-based predictive models used by Novomol-Dx could set new standards for diagnostic accuracy and patient stratification. For investors, the progress in these diagnostic tools could mean long-term value creation by enhancing patient outcomes and reducing healthcare costs associated with misdiagnosis or delayed treatment.
While the immediate focus is on ocular diseases, the adaptability of the biomarker technology for systemic conditions may offer additional avenues for research and development, potentially leading to a broader set of applications and partnerships.
The BMP kit runs on Bio-Techne's Ella™, a benchtop automated immunoassay platform leveraging Bio-Techne's R&D Systems branded reagents to deliver accurate, reliable, and highly reproducible data in less than 90 minutes. Ella's microfluidic-based cartridges with separate channels enable precision multiplexing in a hands-free system, making it ideal for diagnostic clinical use. Novomol-Dx relied on a proprietary algorithm to develop the normative data, disease-associated data, and AI-based predictive algorithms for ocular surface and retinal conditions. The complete solution is branded as BioM-Pathfinder. The novel applications for the BMP kit are in Dry Eye Disease, Diabetic Retinopathy and patient stratification or monitoring associated with ocular surgeries and treatments.
"The BMP kit's ability to produce clinically actionable data using tear samples is a game-changer for the diagnosis of these conditions. This kit fills a significant unmet need, with an estimated 15 million suffering from various ophthalmic diseases in
"There is a great need for improved ocular diagnostic tools, and the BMP kit will save time by enabling an accurate diagnostic solution to the millions impacted by ophthalmic diseases," said Dr. Naren Shetty, Vice-Chairman of Narayana Nethralaya.
"The BMP multi-analyte kit holds great promise for the potential use of Ella in proteomic diagnostic applications," commented Will Geist, President of Bio-Techne's Protein Sciences Segment. "We are happy to partner with this leading ocular biomarker research group and eye care institute to deliver a much-needed diagnostic tool for patients impacted by these diseases."
"We are excited to be able to translate the years of biomarker research in eye diseases to an application that can benefit clinicians and patients," said Dr. Arkasubhra Ghosh, Director of GROW research labs at Narayana Nethralaya Foundation. "The multiple biomarker diagnostic design establishes a platform for future expansion to broader disease applications across ophthalmic conditions, potentially including a non-invasive tear-based diagnosis for systemic conditions."
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated over
About Novomol-Dx
Novomol-Dx is a start-up collaborative initiative of Narayana Nethralaya Foundation to bring out the solutions researched at their Grow Laboratories to the local
About Bio-Techne Corporation (NASDAQ: TECH)
Contact: David Clair, Vice President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-and-novomol-dx-announce-point-of-care-ocular-biomarker-assay-302128379.html
SOURCE Bio-Techne Corporation
FAQ
What is the name of the ocular biomarker kit developed by Bio-Techne and Novomol-Dx?
What platform does the BMP kit run on?
Which ophthalmic diseases does the BMP kit target?
Who is the Chairman at Narayana Nethralaya involved in the development of the BMP kit?
What potential future applications are mentioned for the BMP kit?
